Nektar's (NKTR) shares soar in the year so far on a robust pipeline including several study initiations and strategic collaborations.
Jazz submits a new drug application to the FDA for JZP-110 (solriamfetol) for treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.
Nektar's (NKTR) shares skyrocket in the year so far on a robust pipeline including several study initiations and strategic collaborations.
President Donald Trump's pick for secretary of Health and Human Services collected nearly $2 million in compensation during his final year as president of drug giant Eli Lilly's U.S. operations, new public financial disclosures show.Alex Azar, who left the company in January, also pocketed $1.6 million in severance connected to his departure — and more recently made as much as $1 million from his sale of Eli Lilly stock.Those combined earnings don't include the more than $700,000 that Azar received in assorted payouts at the end of his tenure, ranging from compensation for unused vacation time to an employer match for his savings plan. That represents a substantial slice of Azar's overall financial portfolio, which ranges in value from $9.5 million to more than $20 million, based on estimates in filings with the Office of Government Ethics. And it's likely to ratchet up scrutiny of Azar's ties to the drug industry ahead of confirmation hearings that begin later this month.Multiple Senate Democrats, and independent Vermont Sen. Bernie Sanders, have already declared their opposition to Azar's nomination because of his ties to the drug industry. The Health, Education, Labor and Pensions Committee is set to hold the first confirmation hearing on his nomination Nov. 29.After leaving Indianapolis-based Lilly, Azar leaned heavily on his industry experience to find new work. He collected $46,500 in speaking fees for four events, including ones hosted by the National Association of Specialty Pharmacy and pharma-focused tech company Veeva Systems. Azar also valued his consulting firm's worth at between $15,001 and $50,000. The firm's clientele included the National Pharmaceutical Council and drug company UCB Inc. In an ethics disclosure also filed with the ethics office, Azar pledged to divest interests in a number of health care-related entities, including HMS Holdings, which he served as a board member until he resigned last Friday.Azar also plans to recuse himself for a year from certain issues affecting a series of industry groups, including Eli Lilly, HMS and former consulting clients, unless he first obtains a waiver. Azar said he has already divested his entire $3.4 million stake in Lilly and laid out plans to forfeit or divest all of his HMS equity ownership.He also pledged to refrain until January from participating in matters affecting the Biotechnology Innovation Organization and Healthcare Leadership Council, effectively imposing a one-year cooling off period on himself since his resignation from both health care trade groups.
Regulus Therapeutics Inc. (RGLS) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes
AbbVie's (ABBV) shares inch up with pipeline candidate upadacitinib meeting primary endpoints in a phase III study for treatment of rheumatoid arthritis.
Пара тесно связанных сюжетов о новостях шпионских технологий – про добычу информации из компьютерных устройств по акустическим сигналам работы клавиатуры. (Май 2004) На проходившем в калифорнийском городе Окленде «Симпозиуме по безопасности и приватности» (9-12 мая 2004) интересный доклад представил наш соотечественник Дмитрий Асонов, работающий ныне в Олмейденском исследовательском центре IBM. Совместная работа Асонова и Ракеша … Читать далее Послушай клавиш перебор →
Vertex (VRTX) got a significant boost with positive data from its cystic fibrosis (CF) pipeline while quite a few companies provided regulatory updates.
Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that the FDA has issued a complete response letter (CRL) for the biologics license application (BLA) for Evenity (romosozumab).
Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.
Adamas Pharmaceuticals, Inc. (ADMS) presented expanded analysis from an ongoing open label phase III study EASE LID 2 on its lead candidate, ADS-5102 extended-release capsules.
AbbVie Inc. (ABBV) announced positive top-line results from a phase III study on rheumatoid arthritis candidate, upadacitinib (ABT-494).
The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene
Key highlights in the biotech sector include FDA approval for Regeneron's (REGN) Kevzara and data from Amgen and Celgene.
Adamas Pharmaceuticals, Inc. (ADMS) announced positive data from thephase Ia study evaluating ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy.
Drugmaker’s shares plunge on fears osteoporosis medication will not win approval